Roche and Eli Lilly have received US FDA clearance for an Alzheimer’s blood test targeting phospho-tau 217P. The Elecsys Phospho-Tau (217P) Plasma assay is intended to identify amyloid pathology in adults aged 55 and older presenting with signs, symptoms or complaints of cognitive decline. The clearance expands the market for blood-based biomarker diagnostics, supporting clinicians who want to triage patients for further workup and potentially accelerate access to next-generation anti-amyloid strategies and trials. This update matters for biotech commercialization and adoption dynamics, as payers and health systems increasingly weigh blood tests for scalability and speed compared with cerebrospinal fluid and imaging.